TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31285367

Group type: EXPERIMENTAL
Intervention: Receiving and returning surveys in the clinic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Receiving and returning surveys by email
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Receiving and returning surveys in the clinic (Study 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Receiving surveys in preferred mode (Study 2)
Number of subjects: 0
Study: 29241582

Group type: EXPERIMENTAL
Intervention: 10/20‐PRO (10 g protein followed by 20 g whey protein isolate 120 minutes later)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30‐PRO (30 g protein breakfast)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10‐PRO (10 g protein breakfast, control)
Number of subjects: 12
Study: 25644442

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS)
Number of subjects: 0
Study: 24307240

Group type: EXPERIMENTAL
Intervention: DTaP5 (five-component acellular pertussis vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTwP (whole-cell pertussis vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTaP2 (two-component acellular pertussis vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No vaccine (1997 seroprevalence study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTaP2 or DTaP3 (2007 seroprevalence study)
Number of subjects: 0
Study: 23013200

Group type: EXPERIMENTAL
Intervention: Advanced meter features (AMF group)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Basic meter features (BMF group)
Number of subjects: 211
Study: 20214328

Group type: EXPERIMENTAL
Intervention: Western medical routine therapy combined with QQG
Number of subjects: 82

Group type: COMPARATOR
Intervention: Western medical routine therapy with placebo
Number of subjects: 82
Study: 17576355

Group type: EXPERIMENTAL
Intervention: Complementarity conditions (women high in IO working with a friendly confederate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noncomplementarity conditions (women low in IO working with a friendly confederate, women high in IO working with an unfriendly confederate)
Number of subjects: 0
Study: 15590360

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day + vitamin C 500 mg/day
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day + vitamin E 400 IU/day
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (simvastatin alone)
Number of subjects: 108
Study: 11328193

Group type: EXPERIMENTAL
Intervention: Losigamone (3x500 mg/die)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 9208340

Group type: EXPERIMENTAL
Intervention: Flurythromycin ethylsuccinate
Number of subjects: 152

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 152
Study: 7960298

Group type: EXPERIMENTAL
Intervention: Urban youth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rural youth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semiurban youth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marijuana initiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol initiation
Number of subjects: 0
Study: 3110200

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) 2.25 mg/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31898776

Group type: EXPERIMENTAL
Intervention: PSVPro
Number of subjects: 70

Group type: COMPARATOR
Intervention: PCV
Number of subjects: 70
Study: 31833464

Group type: EXPERIMENTAL
Intervention: Primary care-based group educational intervention about pain neuroscience
Number of subjects: 54

Group type: COMPARATOR
Intervention: Routine medical care (Control)
Number of subjects: 54
Study: 28825650

Group type: EXPERIMENTAL
Intervention: Wellness framing (emphasizing promoting health and quitting support)
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: Punitive framing (emphasizing consequences for violating the policy)
Number of subjects: 1885

Group type: COMPARATOR
Intervention: Control (no message)
Number of subjects: 1885

Group type: EXPERIMENTAL
Intervention: Smokers who correctly reported the message they received
Number of subjects: 1885
Study: 25331194

Group type: EXPERIMENTAL
Intervention: Formulations containing HPC with intrinsic viscosities above 9 dL/g and in quantities above 30%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulations containing HPMC with intrinsic viscosities above 9 dL/g and in quantities above 30%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasted and fed conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPC matrices
Number of subjects: 0
Study: 24780407

Group type: EXPERIMENTAL
Intervention: Low-dose subconjunctival cyclosporine A (CsA) implants
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High-dose subconjunctival cyclosporine A (CsA) implants
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo (carrier only) implants
Number of subjects: 97
Study: 22782607

Group type: EXPERIMENTAL
Intervention: Weaning protocol group (PG)
Number of subjects: 731

Group type: COMPARATOR
Intervention: Non-protocol group (NPG)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 731
Study: 19848312

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 696

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 696
Study: 17695389

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite cement (HAC) reconstruction
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (no HAC reconstruction)
Number of subjects: 130
Study: 15450783

Group type: COMPARATOR
Intervention: Polymorphism ‐602G> A
Number of subjects: 104

Group type: COMPARATOR
Intervention: Haplotypes consisting of ‐602G> A and ‐3542G> A
Number of subjects: 104
Study: 11725616

Group type: EXPERIMENTAL
Intervention: Early removal of nasogastric tube (NGT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Maintenance of nasogastric tube (NGT) until passage of flatus/feces
Number of subjects: 100
Study: 9578342

Group type: EXPERIMENTAL
Intervention: Antioxidant fortified margarine (15 g/d providing 121 mg vitamin C, 31 mg vitamin E, 2.7 mg alpha‐carotene, and 5.3 mg beta‐carotene)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ordinary margarine
Number of subjects: 31
Study: 18800453

Group type: EXPERIMENTAL
Intervention: Losartan potassium 50 mg once or twice daily, or 100 mg once daily
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 2804253

Group type: EXPERIMENTAL
Intervention: Single dose of test or reference drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple dose of test or reference drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose of phenytoin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple dose of phenytoin
Number of subjects: 0
Study: 985661

Group type: EXPERIMENTAL
Intervention: Tobramycin 1.5 mg/kg or 80 mg administered via rapid intravenous injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tobramycin dosage interval of 6 hr with a total dosage of 6 mg/kg per day
Number of subjects: 0
Study: 30444982

Group type: EXPERIMENTAL
Intervention: Lidocaine gel (20 mL of 2% lidocaine gel)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Number of subjects: 215
Study: 28692301

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (3.5 mg or 140,000 IU biweekly for 8 weeks)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3
Number of subjects: 390
Study: 25687878

Group type: EXPERIMENTAL
Intervention: Active GVS during training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo GVS (controls)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Context-Consistent group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Context-Change group
Number of subjects: 30
Study: 24147466

Group type: EXPERIMENTAL
Intervention: High-pitch ECG-synchronized pulmonary CTA
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard pulmonary CTA
Number of subjects: 47
Study: 21135313

Group type: EXPERIMENTAL
Intervention: Open treatment with citalopram followed by up to 3 sequential next‐step treatments.
Number of subjects: 4041
Study: 19467441

Group type: EXPERIMENTAL
Intervention: Periodogram spectral analysis
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Autoregressive (AR) modelling
Number of subjects: 201
Study: 17372316

Group type: EXPERIMENTAL
Intervention: High-fat load (liquid test meal challenge containing 95% fat)
Number of subjects: 701
Study: 15488139

Group type: EXPERIMENTAL
Intervention: Stenting of renal artery
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (medical treatment only)
Number of subjects: 27
Study: 11240973

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg twice a day for 7 days) + Mexiletine (200 mg on the eighth day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Mexiletine (200 mg alone)
Number of subjects: 6
Study: 9448754

Group type: EXPERIMENTAL
Intervention: 3D fat-suppressed echo planar imaging (EPI) sequence
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3D fat-suppressed gradient echo (GE) sequence
Number of subjects: 20
Study: 7755478

Group type: EXPERIMENTAL
Intervention: Cilazapril (CIL) 10 mg per day (n=6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PL) (n=7)
Number of subjects: 13
Study: 2790919

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulphate, 20 mg/day for one year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1255309

Group type: EXPERIMENTAL
Intervention: Chloramphenicol treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ampicillin treatment
Number of subjects: 50
Study: 30678744

Group type: EXPERIMENTAL
Intervention: Individual psychological treatments (Healthy Activity Program for depression)
Number of subjects: 222

Group type: COMPARATOR
Intervention: mhGAP-based services by primary health workers
Number of subjects: 222
Study: 27979755

Group type: EXPERIMENTAL
Intervention: Non-nutritive sweetened (NNS) beverages
Number of subjects: 432

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: NNS beverages
Number of subjects: 432

Group type: COMPARATOR
Intervention: NNS beverages and water
Number of subjects: 432
Study: 26076755

Group type: EXPERIMENTAL
Intervention: Contextual Cognitive Behavioural Therapy (CCBT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 89
Study: 23138352

Group type: EXPERIMENTAL
Intervention: BP + PPI (sodium risedronate with sodium rabeprazole)
Number of subjects: 180

Group type: COMPARATOR
Intervention: BP (sodium risedronate only)
Number of subjects: 180
Study: 16855451

Group type: EXPERIMENTAL
Intervention: Sertraline (SERT)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Nortriptyline (NTP)
Number of subjects: 109
Study: 12908854

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily and caffeine 100 mg three times daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily and caffeine 100 mg three times daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Caffeine alone
Number of subjects: 24
Study: 10472157

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy
Number of subjects: 25
Study: 12799847

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tilidine/naloxone 50 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Codeine 50 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tilidine/naloxone 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Codeine 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tilidine/naloxone 50 mg and 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Codeine 50 mg and 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg and 100 mg
Number of subjects: 30
Study: 1829465

Group type: EXPERIMENTAL
Intervention: 30 mg/day acitretin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Acitretin therapy after placebo
Number of subjects: 65
Study: 6307458

Group type: EXPERIMENTAL
Intervention: Combined epidural and splanchnic nerve blockade (Group E&S)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epidural analgesia alone (Group E)
Number of subjects: 12

Group type: COMPARATOR
Intervention: General anaesthesia (Group G)
Number of subjects: 12
Study: 31235487

Group type: EXPERIMENTAL
Intervention: Weighted polygenic risk score (PRS) for metabolically favorable adiposity
Number of subjects: 341872

Group type: EXPERIMENTAL
Intervention: IGFBP-3 concentrations
Number of subjects: 341872
Study: 28214615

Group type: EXPERIMENTAL
Intervention: Nursing care and follow-up program
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 25243325

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg od
Number of subjects: 509

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) 10 mg od
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Both TDF and ADV
Number of subjects: 509
Study: 23588709

Group type: EXPERIMENTAL
Intervention: 3-mm ports (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5-mm ports (Group B)
Number of subjects: 80
Study: 21083860

Group type: EXPERIMENTAL
Intervention: Oral metformin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 100
Study: 20509323

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC) in women
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC) in men
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Adiposity markers in women
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Adiposity markers in men
Number of subjects: 80
Study: 16442114

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) with estradiol +/- medroxyprogesterone
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 83
Study: 14579993

Group type: EXPERIMENTAL
Intervention: High starting dose: 1 mg budesonide inhalation suspension twice daily for 8 days (n = 11)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low starting dose: 0.25 mg budesonide inhalation suspension twice daily for 8 days (n = 11)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 29
Study: 11052582

Group type: EXPERIMENTAL
Intervention: NE‐1530 (n=254)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Placebo (n=253)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: NE‐1530
Number of subjects: 507

Group type: COMPARATOR
Intervention: NE‐1530 and Placebo
Number of subjects: 507
Study: 8797622

Group type: EXPERIMENTAL
Intervention: Infrared ear thermometers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rectal temperature
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pulmonary artery temperature
Number of subjects: 20
Study: 1283931

Group type: EXPERIMENTAL
Intervention: Local, laparoscopic Prostaglandin‐injection
Number of subjects: 33
Study: 6094995

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30482661

Group type: EXPERIMENTAL
Intervention: Bladder-sparing tri-modality therapy (TMT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Radical cystectomy (RC)
Number of subjects: 67
Study: 29505578

Group type: EXPERIMENTAL
Intervention: DDD (Door-to-Door Delivery)
Number of subjects: 2035

Group type: COMPARATOR
Intervention: FPD (Fixed-Point Delivery)
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: DOT (Directly Observed Treatment)
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: NDOT (Non-Directly Observed Treatment)
Number of subjects: 2035
Study: 25487682

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 24518370

Group type: EXPERIMENTAL
Intervention: 800 μg or 1600 μg of salbutamol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1600 μg of salbutamol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control environment (35°C, 40% relative humidity) during exercise
Number of subjects: 32
Study: 22912697

Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 640

Group type: COMPARATOR
Intervention: Chloroquine + Artesunate
Number of subjects: 640

Group type: COMPARATOR
Intervention: Chloroquine + Azithromycin
Number of subjects: 640

Group type: COMPARATOR
Intervention: Chloroquine + Atovaquone-Proguanil
Number of subjects: 640

Group type: COMPARATOR
Intervention: Chloroquine monotherapy
Number of subjects: 640

Group type: COMPARATOR
Intervention: Chloroquine combinations
Number of subjects: 640

Group type: COMPARATOR
Intervention: Chloroquine-Azithromycin
Number of subjects: 640
Study: 20016461

Group type: EXPERIMENTAL
Intervention: AKL-0707 (GH-releasing hormone super-agonist)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 17401781

Group type: EXPERIMENTAL
Intervention: Olanzapine (mean dose 12.3 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone (mean dose 5.2 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study: 16280435

Group type: EXPERIMENTAL
Intervention: Fortified maize-meal porridge
Number of subjects: 361

Group type: COMPARATOR
Intervention: Control (unfortified porridge)
Number of subjects: 361
Study: 11849248

Group type: EXPERIMENTAL
Intervention: lanreotide SR
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: octreotide LAR
Number of subjects: 20

Group type: COMPARATOR
Intervention: lanreotide SR and octreotide LAR
Number of subjects: 20
Study: 10194151

Group type: EXPERIMENTAL
Intervention: Intensive support including CPAP education at home, a 3-night trial of CPAP in a sleep center, and additional home visits
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual support
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients who initiated their own referrals
Number of subjects: 80
Study: 7756097

Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) formulation (100 mg levodopa/25 mg genserazide)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Controlled Release (CR) formulation (300 mg levodopa/75 mg benserazide)
Number of subjects: 12
Study: 2272818

Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Training (PRT)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 202
Study: 7465474

Group type: EXPERIMENTAL
Intervention: 30 g of glucose a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 129 g of glucose a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 30644570

Group type: EXPERIMENTAL
Intervention: Combination therapy of mirabegron (50 mg) and solifenacin (5 mg)
Number of subjects: 1794

Group type: COMPARATOR
Intervention: Solifenacin monotherapy
Number of subjects: 1794

Group type: COMPARATOR
Intervention: Mirabegron monotherapy
Number of subjects: 1794
Study: 27830922

Group type: EXPERIMENTAL
Intervention: Psychomotor treatment (group A)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Behavioral and educational counseling (group B)
Number of subjects: 67
Study: 25965713

Group type: EXPERIMENTAL
Intervention: Structured weight management
Number of subjects: 69

Group type: COMPARATOR
Intervention: General lifestyle advice
Number of subjects: 69
Study: 22921175

Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 0

Group type: COMPARATOR
Intervention: No flow
Number of subjects: 0
Study: 21205408

Group type: EXPERIMENTAL
Intervention: Educational and environmental intervention focusing on menu planning, food presentation, and motivational strategies.
Number of subjects: 2510

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 2510
Study: 19934710

Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory (PedsQL)
Number of subjects: 52
Study: 16907972

Group type: EXPERIMENTAL
Intervention: NUDOV (interactive case simulation system)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 116
Study: 15271731

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 150 microg diluted with 9 mL of normal saline 30 min before surgery and PCEA with morphine (0.1 mg/mL) and clonidine (1.5 microg/mL) in 0.2% ropivacaine 100 mL after surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline 10 mL before surgery and PCEA with morphine and ropivacaine after surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural clonidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 40
Study: 11563588

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose melphalan with autologous stem cell transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel treatment strategies (nonmyeloablative allogeneic transplantation, vaccination)
Number of subjects: 0
Study: 9436891

Group type: EXPERIMENTAL
Intervention: HIV Living Will
Number of subjects: 101

Group type: COMPARATOR
Intervention: Centre for Bioethics Living Will
Number of subjects: 101
Study: 8513525

Group type: COMPARATOR
Intervention: Ondansetron (antiemetic, selective serotonin 5-HT3 receptor antagonist) administered via rapid intravenous infusion over two minutes.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group) administered via rapid intravenous infusion.
Number of subjects: 0
Study: 14591143

Group type: EXPERIMENTAL
Intervention: 600 mg Suloctidil daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 450 mg Suloctidil daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29370256

Group type: EXPERIMENTAL
Intervention: Mindfulness-instructions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control-instructions
Number of subjects: 50